Search Results

Hematogenix® announces the offering of COVID-19 antibody testing from blood samples using the Elecsys® Anti-SARS-CoV-2 test developed by Roche. The offering of this test, which the U.S. Food & Drug Administration (FDA) has approved with emergency use authorization 1 , reaffirms Hematogenix’s commitment to the community during t

Hematogenix is one of the companies that is responding to recent advancements that have occurred in China’s clinical trials regulations.

Hematogenix®, a global leader in the field of cancer research and immuno-oncology testing, announces the availability of the assessment of B-cell maturation antigen (BCMA) by flow cytometry and immunohistochemistry (IHC) at its facilities globally.

Hematogenix®- a global leader in the field of integrated pathology services for drug development and immuno-oncology testing, announced the launch of the companion diagnostic test for the drug TECENTRIQ®.

Widespread accurate testing for SARS-CoV-2, the virus that causes COVID-19, is one critical aspect needed to limit the spread of the disease.

Hematogenix Laboratory Services® - an industry leader in the field of integrated pathology services for drug development and immuno-oncology testing, launches monitoring of minimal residual disease (MRD) for Chronic Lymphocytic Leukemia (CLL).